Published by Global Banking & Finance Review®
Posted on August 26, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on GoogleThe EU has approved Gilead's lenacapavir injection for HIV prevention, expected to significantly impact global HIV transmission rates.
By Deena Beasley
(Reuters) -The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
The drug, known scientifically as lenacapavir, will be sold in Europe under the brand name Yeytuo. It was approved in June by regulators in the U.S., where it is marketed as Yeztugo.
The EC approval applies to use in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein. Before the drug can be made available to patients, Gilead will need to establish pricing and reimbursement terms with health systems in each country.
In the United States, Gilead's list price for Yeztugo is over $28,000 a year. Some U.S. insurers are holding off on covering the new injection, citing its high price compared to generic pills.
Analysts project the drug will have sales of over $4 billion a year by 2029, according to LSEG.
The European Commission approved the drug for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV in adults and adolescents at increased risk of contracting the deadly virus.
Lenacapavir proved nearly 100% effective at preventing HIV in large trials last year, raising new hope of interrupting transmission of the virus that infects 1.3 million people a year.
Gilead said its EU application was reviewed under an accelerated timeline and was granted an additional year of market protection.
The company said it has also filed for regulatory review of twice-yearly lenacapavir for PrEP with authorities in Australia, Brazil, Canada, South Africa and Switzerland and is preparing filings in Argentina, Mexico and Peru.
The World Health Organization in July recommended lenacapavir as an additional PrEP option for HIV prevention.
Gilead said it intends to pursue submissions to regulatory authorities in low- and middle-income countries including priority registrations covering 18 countries that represent 70% of the HIV burden of the 120 countries named in its previously announced voluntary licensing agreements.
The company plans, with the Global Fund to Fight AIDS, Tuberculosis and Malaria, to supply lenacapavir for up to two million people in low-income countries over three years as generic drugmakers gear up production under the royalty-free agreements.
(Reporting By Deena Beasley; Editing by Chris Reese)
Lenacapavir is a twice-yearly injection approved for preventing HIV infection, specifically for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV in adults and adolescents at increased risk.
Analysts project that lenacapavir will generate sales of over $4 billion a year by 2029.
In the United States, Gilead's list price for lenacapavir, marketed as Yeztugo, is over $28,000 a year.
Gilead plans to pursue regulatory submissions for lenacapavir in low- and middle-income countries, covering 18 countries that represent 70% of the HIV burden.
The World Health Organization recommended lenacapavir as an additional option for HIV prevention in July.
Explore more articles in the Headlines category
